Harry P. Erba

18.9k total citations · 3 hit papers
252 papers, 6.6k citations indexed

About

Harry P. Erba is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Harry P. Erba has authored 252 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 198 papers in Hematology, 100 papers in Molecular Biology and 81 papers in Genetics. Recurrent topics in Harry P. Erba's work include Acute Myeloid Leukemia Research (177 papers), Chronic Myeloid Leukemia Treatments (70 papers) and Chronic Lymphocytic Leukemia Research (50 papers). Harry P. Erba is often cited by papers focused on Acute Myeloid Leukemia Research (177 papers), Chronic Myeloid Leukemia Treatments (70 papers) and Chronic Lymphocytic Leukemia Research (50 papers). Harry P. Erba collaborates with scholars based in United States, France and Italy. Harry P. Erba's co-authors include Daniel J. DeAngelo, Martin S. Tallman, Larry Kedes, Peter W. Gunning, Frederick R. Appelbaum, Robert K. Stuart, Megan Othus, Stephen H. Petersdorf, Roland B. Walter and Joseph G. Gall and has published in prestigious journals such as Nature, Cell and The Lancet.

In The Last Decade

Harry P. Erba

235 papers receiving 6.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

2014 595 citations Meir Wetzler, Harry P. Erba et al. Blood profile →
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

2013 460 citations Kenneth J. Kopecky, Cheryl L. Willman et al. Blood profile →
Acute myeloid leukaemia

2023 193 citations Harry P. Erba et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Harry P. Erba	3.6k	3.3k	1.6k	1.4k	1.1k	252	6.6k
Hitoshi Kiyoi	5.4k 1.5×	4.4k 1.3×	2.1k 1.3×	2.0k 1.4×	1.4k 1.3×	277	9.0k
Michael Heuser	4.2k 1.1×	3.6k 1.1×	1.0k 0.6×	1.5k 1.1×	819 0.8×	250	6.7k
Clayton A. Smith	2.9k 0.8×	2.7k 0.8×	1.1k 0.7×	1.1k 0.8×	412 0.4×	129	5.5k
Pamela S. Becker	3.7k 1.0×	2.4k 0.7×	1.5k 0.9×	1.3k 0.9×	658 0.6×	221	6.0k
John Anastasi	2.9k 0.8×	2.6k 0.8×	1.0k 0.6×	1.1k 0.8×	865 0.8×	97	6.0k
Andre C. Schuh	2.5k 0.7×	4.9k 1.5×	1.4k 0.8×	947 0.7×	793 0.7×	181	7.8k
Raphaël Itzykson	2.9k 0.8×	3.5k 1.1×	2.0k 1.2×	1.5k 1.1×	393 0.4×	139	6.7k
Rosemary E. Gale	5.2k 1.4×	3.2k 1.0×	735 0.4×	2.3k 1.7×	1.4k 1.3×	115	7.4k
Norma C. Gutiérrez	3.4k 0.9×	3.3k 1.0×	1.7k 1.1×	1.2k 0.9×	344 0.3×	179	5.6k
Joop H. Jansen	2.9k 0.8×	4.4k 1.4×	1.1k 0.7×	951 0.7×	530 0.5×	155	7.0k

Countries citing papers authored by Harry P. Erba

Since Specialization

Citations

This map shows the geographic impact of Harry P. Erba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harry P. Erba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harry P. Erba more than expected).

Fields of papers citing papers by Harry P. Erba

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harry P. Erba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harry P. Erba. The network helps show where Harry P. Erba may publish in the future.

Co-authorship network of co-authors of Harry P. Erba

This figure shows the co-authorship network connecting the top 25 collaborators of Harry P. Erba. A scholar is included among the top collaborators of Harry P. Erba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harry P. Erba. Harry P. Erba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Li, Muharrem Müftüoğlu, Koichi Iwanaga, et al.. (2025). Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3 -ITD Mutant/ TP53 Wild-type Acute Myeloid Leukemias. Clinical Cancer Research. 31(14). 3033–3047.

Borate, Uma, John L. Reagan, Richard F. Little, et al.. (2025). A randomized Phase II trial of ASTX727 and venetoclax with or without enasidenib for newly diagnosed older adults with IDH2 mutant Acute Myeloid Leukemia: A myelomatch substudy (MM1OA-S03). Blood. 146(Supplement 1). 3466–3466.

Mannis, Gabriel N., Nikolai A. Podoltsev, Deepa Jeyakumar, et al.. (2025). Tuscany Study demonstrates safety and efficacy of tuspetinib plus standard of care venetoclax and azacitidine in patients with newly diagnosed AML ineligible for induction chemotherapy. Blood. 146(Supplement 1). 1645–1645.

Othus, Megan, Harry P. Erba, Guillermo Garcia‐Manero, et al.. (2024). Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203. Leukemia. 38(7). 1488–1493.

Erba, Harry P., Elżbieta Patkowska, Jörge E. Cortes, et al.. (2024). AML-202 QuANTUM-First: Efficacy by Age in Newly Diagnosed (nd) Patients With FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication–Positive (FLT3-ITD+) Acute Myeloid Leukemia (AML). Clinical Lymphoma Myeloma & Leukemia. 24. S299–S299.

Jonas, Brian A., Jing‐Zhou Hou, Gail J. Roboz, et al.. (2023). A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia. Hematological Oncology. 41(4). 743–752. 12 indexed citations

Erba, Harry P., Hervé Dombret, Alexander E. Perl, et al.. (2023). Quantum-First: Safety By Treatment Phase and By Age in Newly Diagnosed (nd) Patients (pts) with FMS-like Tyrosine Kinase 3-Internal Tandem Duplication ( FLT3-ITD) Positive Acute Myeloid Leukemia (AML). Blood. 142(Supplement 1). 972–972. 1 indexed citations

Advani, Anjali S., Anna Moseley, Kristen M. O’Dwyer, et al.. (2021). A Phase 2 Study of Dasatinib, Prednisone, and Blinatumomab for Older Patients with Philadelphia-Chromosome (Ph) Positive or Ph-like Acute Lymphoblastic Leukemia (ALL) (with Dasatinib Sensitive Fusions/ Mutations). Blood. 138(Supplement 1). 3397–3397. 9 indexed citations

Hay, Annette E., Sarit Assouline, Roland B. Walter, et al.. (2019). Accrual Barriers and Detection of Early Toxicity Signal in Older Less-Fit Patients Treated with Azacitidine and Nivolumab for Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) in the SWOG 1612 Platform Randomized Phase II/III Clinical Trial. Blood. 134(Supplement_1). 3905–3905. 7 indexed citations

10.

Othus, Megan, Guillermo Garcia‐Manero, John E. Godwin, et al.. (2019). Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data. Blood. 134(Supplement_1). 291–291. 1 indexed citations

11.

Swords, Ronan, Steven Coutré, Michael B. Maris, et al.. (2018). Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML. Blood. 131(13). 1415–1424. 157 indexed citations

12.

Ritchie, Ellen K., Rosalind Catchatourian, Rebecca B. Klisovic, et al.. (2017). Results from Enestgoal: A Phase 2 Study of Treatment-Free Remission (TFR) in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Switched from Imatinib to Nilotinib. Blood. 130. 2875–2875. 7 indexed citations

13.

Cortes, Jörge E., Elie Traer, Eunice S. Wang, et al.. (2017). IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood. 130. 1312–1312. 7 indexed citations

14.

Othus, Megan, Guillermo Garcia‐Manero, John E. Godwin, et al.. (2017). Associations between Complete Remissions (CRs) with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia and 2-3 Year Survival (“Potential Cure”) over the Past Four Decades: Analysis of SWOG Trial Data. Blood. 130. 1301–1301. 1 indexed citations

15.

Pogosova‐Agadjanyan, Era L., Anna Moseley, Megan Othus, et al.. (2017). Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report. Biopreservation and Biobanking. 16(1). 42–52. 6 indexed citations

16.

Prébet, Thomas, Zhuoxin Sun, Rhett P. Ketterling, et al.. (2015). Azacitidine with or without Entinostat for the treatment of therapy‐related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. British Journal of Haematology. 172(3). 384–391. 56 indexed citations

17.

Saiya-Cork, Kamlai, Brian Parkin, Peter Ouillette, et al.. (2011). A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia. Clinical Cancer Research. 17(9). 2679–2692. 27 indexed citations

18.

O’Brien, Susan, Ellin Berman, Hossein Borghaei, et al.. (2009). Chronic Myelogenous Leukemia. Journal of the National Comprehensive Cancer Network. 7(9). 984–1023. 175 indexed citations

19.

Ouillette, Peter, Harry P. Erba, Lisa Kujawski, et al.. (2008). Integrated Genomic Profiling of Chronic Lymphocytic Leukemia Identifies Subtypes of Deletion 13q14. Cancer Research. 68(4). 1012–1021. 135 indexed citations

20.

Kujawski, Lisa, Peter Ouillette, Harry P. Erba, et al.. (2008). Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood. 112(5). 1993–2003. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact